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Abstract
Background: Very few data exist on the management of community-acquired pneumonia (CAP) in patients
admitted to hospitals in the Gulf region. The objectives of this study were to describe treatment patterns for
CAP in 38 hospitals in five Gulf countries (United Arab Emirates, Kuwait, Bahrain, Oman, and Qatar) and to
compare the findings to the most recent Infectious Diseases Society of America (IDSA) / American Thoracic
Society (ATS) guidelines.
Methods: This was a prospective, observational study conducted between January 2009 and February 2011.
Adult patients hospitalised (excluding intensive care units) for CAP and subsequently discharged were included.
Data were collected retrospectively at hospital discharge, and prospectively during two follow-up visits. Data on
medical history, mortality-risk scores, diagnostic criteria, antibiotic treatment, isolated pathogens and clinical and
radiographic outcomes were collected. Care practices were compared to the IDSA/ATS guidelines.
Results: A total of 684 patients were included. The majority (82.9 %) of patients were classified as low risk for
mortality (pneumonia severity index II and III). The majority of patients fulfilled criteria for treatment success at
discharge, although only 77.6 % presented a normalised leukocyte count. Overall, the management of CAP in
Gulf countries is in line with the IDSA/ATS guidelines. This applied to the diagnosis of CAP, to the identification of
high-risk CAP patients, to the identification of etiologic agent responsible for CAP and to the type of treatment
despite the fact that combinations of antimicrobial agents were not consistent with the guidelines in 10 % of
patients. In all patients, information about Gram’s staining was not captured as recommended by the IDSA/ATS
and in the majority of patients (>85 %) chest radiography was not systematically performed at the post-discharge
follow-up visits.
Discussion: The management of CAP in the Gulf region is globally in line with current IDSA/ATS guidelines,
although rates of pathogen characterisation and post-discharge follow-up need to be improved.
Conclusion: Compliance with established guidelines should be encouraged in order to improve the management
of the disease in this region.
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Background
Community-acquired pneumonia (CAP) is a common
and potentially serious illness acquired outside a hospital
or long-term care facility or other recent contact with
the health care system [1].
Improving the care of adult patients with CAP has
been the focus of many different organisations, and sev-
eral have developed guidelines for the treatment of CAP.
In North America, CAP guidelines were first developed
in 1993, and in 2007, the joint Infectious Diseases Soci-
ety of America (IDSA) / American Thoracic Society
(ATS) guidelines [2, 3] were proposed. The process,
which began in the United States and Canada, has now
been implemented in numerous countries throughout
the world [4]. In the Gulf region, the IDSA/ATS guide-
lines are considered as one of the most important prac-
tice guidelines for the diagnosis and management of
CAP. Previous studies have shown that implementing
IDSA/ATS guidelines for hospitalised CAP patients in
general wards is associated with good patient outcomes
[5–7]. For instance, a study conducted in the United
States has evaluated the impact of use of the IDSA/ATS
therapeutic guidelines among 35 477 inpatients with
CAP. This study showed that, after adjustment for se-
verity of illness and other potential confounders,
guideline-concordant therapy was associated with a de-
crease of in-hospital mortality (odds ratio [OR], 0.70;
95 % confidence interval [CI], 0.63–0.77) and of sepsis
(OR, 0.83; 95 % CI, 0.72–0.96), with a reduction in both
length of stay and duration of parenteral therapy by ap-
proximately 0.6 days (p < 0.001 for both comparisons)
[5]. Several studies on the outcomes of patients with
CAP and adherence to the 2007 IDSA/ATS guidelines
[2] have been published [8–10]. However, to our know-
ledge, only one published study in a Gulf Arab state
(Oman) [11] has been conducted to compare the in-
patient management of CAP with established clinical
guidelines (the Gulf Cooperation Council CAP guide-
lines (GCC CAP) [12]).
The main objectives of our study were to describe
treatment practices in CAP patients admitted to hospi-
tals (but not to intensive care units) in five countries in
the Gulf region (United Arab Emirates, Kuwait, Bahrain,
Oman and Qatar) and to compare the findings to the
2007 IDSA/ATS treatment guidelines.
Methods
Study design
The Gulf practices of Treatment of in-hospital Community-
Acquired Pneumonia (G-TinCAP) study was a multicen-
tre, prospective, observational study conducted in 38 hos-
pitals. All these were large urban hospitals involved in the
management of CAP and who admitted adequate number
of CAP patients. These hospitals included both public and
private institutions, teaching hospitals, community hospi-
tals and military hospitals. A total of 21 centres from
United Arab Emirates, ten centres from Kuwait, three
centres from Bahrain, three centres from Oman, and one
centre from Qatar were involved. In principle, these hospi-
tals adhered to the IDSA/ATS guidelines [2] for manage-
ment of infectious diseases published in 2007, as well as
local Gulf Cooperation Council CAP guidelines [12]. The
study was conducted between January 2009 and February
2011.
Study population
Participating investigators were selected from general
practitioners, internists and pulmonologists practicing in
hospitals from five Gulf countries. Patients who com-
pleted a hospitalisation for CAP resulting in discharge
were eligible for the study. Adult patients (aged over
18 years) diagnosed with a CAP class II, ІІІ, ІV or V ac-
cording to the Fine score criteria of severity [13], were
included in the study if they provided a signed informed
consent.
The diagnosis of CAP was based on:
a) At least one of the following symptoms:
1. Presence of fever (pyrexia);
2. Shivering;
3. Presence of severe cough (with or without
expectoration) or persistent cough with
discolored phlegm; pleuritic chest pain or
dyspnea.
b) Presence of auscultation findings of pneumonia
namely crepitations or later inspiratory crackles in
involved areas and bronchial breathing.
c) Chest radiograph with evidence of new infiltrate
changes compatible with CAP (not required for all
patients).
The exclusion criteria consisted of:
 Participation in another clinical trial;
 Patients with CAP categorised in class І according to
Fine criteria [13], or in any class, who required
treatment in an Intensive Care Unit (ICU) at any
time;
 Patients previously hospitalised for any reason
within 15 days prior to the current hospitalisation;
 Patients with lung cancer, proven tuberculosis or
HIV
Individual patients who were admitted on more than
one occasion with a CAP could only be included once.
The analysis was performed on all patients discharged
from hospital.
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Data collection
Elligible patients who agreed to participate in the study
were invited to take part in the study and a case report
form was completed at discharge from hospital, during
the first follow-up visit between 7 and 10 days after dis-
charge, and during a final follow-up made either by
telephone or at a hospital visit around 3 weeks after
discharge by the investigator. Data on patient’s socio-
demographic characteristics, medical history, diagnosis,
comorbidities and treatment were collected. Specific in-
formation on the CAP was also collected including ini-
tial evaluation of the CAP, risk class according to the
Fine criteria [13]; clinical and radiographic symptoms
of CAP as well as evidence of pulmonary infiltrates
compatible with CAP and bacteriological evaluation.
Concomitant medications and antimicrobial treatments
up to 14 days before study entry were also documented.
Data were validated for quality by checking for com-
pleteness, discrepancies, and inconsistencies, which, if
present, were queried to the investigators for clarifica-
tion before the data were validated in the database.
Study outcomes
Data regarding the management of CAP in the Gulf coun-
tries was documented and compared with treatment rec-
ommendations of the IDSA/ATS guidelines published in
2007. Overall, CAP diagnosis criteria, as well as criteria
for the identification of high-risk patients, tests performed
for the identification of aetiological agent responsible for
CAP and the treatment used were described and com-
pared with the international guidelines.
The overall therapeutic outcome on CAP (success or
failure) is documented by participating physicians at
discharge visit and subsequent follow up visits. The
therapeutic outcome was considered successful if the
“patient’s clinical stability at discharge” criteria had been
achieved. These were stable vital signs over 24 h, ability
to take oral medication, normal eating and drinking be-
havior, return to usual mental state, and normalisation
of leukocyte count. The therapeutic outcome was con-
sidered as failure in case of development of complica-
tions such as pulmonary abscess or sepsis, progression
of clinical symptoms, radiological changes, need to
change the antibiotic therapy, rehospitalisation due to
pneumonia, and death. The switch from intravenous to
oral administration was also evaluated according to four
criteria, consisting of patient’s ability to eat and drink,
negative hemocultures, temperature ≤38°С (during the
last 16 h) and improvement of symptoms. Fever and
leukocytosis were not considered as a reason for switch.
Statistical analysis
The sample size was determined a priori assuming that
50 % of hospitalised CAP patients are high-risk patients
(pneumonia severity index (PSI) IV, V), as reported in a
previous study by Etzion et al.[14]. In order to estimate
a proportion of high-risk patients of 50 % with a 95 %
confidence interval of ±4 %, it was estimated that a tar-
get sample of 583 patients would be required to be
included, which was rounded up to 600 patients. Assum-
ing a dropout rate of 15 %, about 690 patients were
planned to be recruited for this study. All enrolled
patients were included in the final analysis, which was
performed on data pooled from all five participating
countries. Data were summarized using descriptive sta-
tistics including arithmetic means, ranges, frequencies
and percentages. Statistical analysis was performed using
SPSS software, version 16 (SPSS Inc., Chicago, USA).
Ethics
The study was performed in accordance with the
Guidelines of Good Epidemiology Practice [15] and
corresponding local regulations, including data confi-
dentiality. This study was approved by the Institutional
Review Boards of all hospitals when required according
to local regulations and a written informed consent was
obtained from all eligible patients.
Results
Characteristics of the study population
A total of 684 patients were enrolled in the study by 39
physicians from 38 centres located in the five participat-
ing countries. All participating subjects met eligibility
criteria of the study and no major protocol deviations
were identified during the study. Of the 684 patients,
444 were from the United Arab Emirates, 150 patients
were from Kuwait, 44 from Bahrain, 28 from Oman and
18 from Qatar. The baseline characteristics of participat-
ing patients are presented in Table 1.
The classification of CAP risk according to the Fine
criteria [13], as recommended in the IDSA/ATS guide-
lines, is presented in Table 2. The majority (82.9 %) of
patients were classified as low risk for mortality [13]
(classes II and III). During chest auscultation, positive
clinical findings such as crepitations were documented by
80 % of study participants. At admission, 70.6 % (n = 483)
of the patients showed new infiltrative changes in the
chest radiogram; for the rest of the population, a radio-
gram was not performed or did not show new infiltrative
changes. In addition, 12.1 % (n = 83) of patients received
antibiotic treatment prior to hospital admission (Table 2).
Pathogen isolation was performed in 88 patients. Only
78 specimens collected (mainly sputum) were analyse-
able, of which Streptococcus pneumonia was present in
almost half of them (46.1 %; n = 36 specimens), followed
by the ccombination of S. pneumoniae and Klebsiella
which was isolated in 17 % of cases (n = 13 specimens),
and Klebsiella alone and Mycoplasma alone which were
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isolated in 9 % (n = 7 specimens) and 8 % (n = 6 speci-
mens) of cases respectively.
Empirical therapy and process of care
The mean length of hospital stay for the treatment of
CAP was 3.9 ± 4.4 days ranging from 1 to 19 days. For
all study participants, intravenous empirical antibiotic
treatment was initiated immediately upon hospital ad-
mission, before the pathogen was identified. The mean
duration of intravenous treatment was 3.5 days (81 h),
ranging from 3 to 6 days. In 80 % of patients, switching
to oral antibiotic therapy occurred within 3 days (72 h).
The physicians’ decision to switch was mainly driven by
lack of improvement of basic clinical CAP symptoms.
The main factor determining the choice of CAP anti-
microbial therapy was the type of previous antibiotic
therapy, reported in 406 (59.4 %) patients, followed by
interaction with other medicines, reported in 285
(41.7 %) patients. In the vast majority of patients,
(94.4 %; n = 646), antimicrobial therapy initiated on the
day of hospitalisation was not changed. The remaining
patients (n = 38) required changes from one class of
antibiotic to another, most frequently within the 24 h
following the isolation of organism, based on the sensi-
tivity of pathogens to particular antimicrobial agents.
The majority of patients (77.9 %, n = 533) were
treated with a single antimicrobial agent, whereas about
one fifth of patients (20.3 %; n = 139) were treated with
two agents and the rest (1.8 %; n = 12) with three
agents. In the group of patients treated with a single
antimicrobial agent, levofloxacin was the most fre-
quently used (65.7 %; n = 350), followed by ceftriaxone
(16.1 %; n = 86) and moxifloxacin (13.1 %; n = 70).
Other single antibiotics, such as co-amoxiclav, were
used in less than 2 % of patients. Use of the most fre-
quent combinations of two antimicrobial agents is
shown in Table 3. Levofloxacin was most frequently
used in combinations with other antibiotics (57.7 % of
cases), principally with a β-lactam (50.5 % of cases, cor-
responding to around 10 % of the entire study popula-
tion). At discharge, most patients fulfilled the criteria
for treatment success. The determination of success
was based on patient’s clinical stability and discharge
criteria. Thus, vital signs were stable over 24 h in
99.3 % of patients, 99.7 % were able to take oral antibi-
otics, 99.3 % were able to eat and drink normally,
94.1 % were evaluated as being in their normal mental
condition and leukocyte count had normalised in
77.6 % of patients. At the time of discharge, all patients
underwent a chest radiogram, although it should be
noted that complete radiographic recovery had only oc-
curred in 31.4 % (n = 215 patients) of patient.
Table 1 Baseline characteristics of the study population
Total
(N = 684)
Gender (men) 505 (73.8 %)
Age (years) 41.5 ± 14
Living in own home 464 (67.8 %)
Living in a skilled nursing facility 220 (32.2 %)
Current smoker 316 (46.2 %)
Imuunocompetent 669 (97.8 %)
Principal CAP associated disease
Cardiovascular disease 71 (10.4 %)
Diabetes mellitus 85 (12.4 %)
Bronchopulmonary disease 11 (1.6 %)
Renal failure 13 (1.9 %)
Chronic liver disease 11 (1.6 %)
Data are presented as numbers of patients (%) except for age, which is
presented as mean ± SD. CAP indicates community-acquired pneumonia
Table 2 Baseline risk classification, diagnostic criteria of CAP
and pre-study use of antibiotics
N = 684
FINE criteria [13]
Mean score [range] 69 ± 27
[18–167]
Category II 386 (56.4 %)
Category III 181 (26.5 %)
Category IV 100 (14.6 %)
Category V 17 (2.5 %)
Clinical and radiologic CAP criteria N = 684
Pyrexia 676 (98.8 %)
Shivering 631 (91.9 %)
Severe cough or persistent cough with discolored
phlegm
682 (99.7 %)
Crepitation/late inspiratory crackles or bronchial
breathing
553 (80.9 %)
Chest radiograph (X-ray) 483
(70.6 %)a
Antibiotic therapy used 14 days prior to study entry N = 83
Co-amoxiclav 23 (27.7 %)
Cefuroxime 16 (19.3 %)
Clarithromycin 15 (18.1 %)
Amoxycillin 10 (12.1 %)
Ceftriaxone 7 (8.4 %)
Azithromycin 5 (6.0 %)
Levofloxacin 3 (3.6 %)
Cefixime 2 (2.4 %)
Moxifloxacin 1 (1.2 %)
Penicillin 1 (1.2 %)
Data are presented as numbers of patients (%) unless otherwise indicated.
CAP community-acquired pneumonia
aOnly patients with new infiltrative changes in the radiogram of the chest
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At hospital discharge, a total of 626 patients (91.5 %)
were prescribed home antimicrobial therapy, most fre-
quently oral therapy unless the patient could not tolerate
this route of administration. Of these, 573 patients
(91.5 %) used a single antimicrobial agent and 53 (8.5 %)
used a combination of two agents. The mean duration of
treatment was 7.4 days [6–10 days] and 75 % of patients
were prescribed a home antibiotic for 5–10 days. Among
the recorded single antimicrobial agents in 519 patients,
levofloxacin was used in the majority of patients (62.6 %;
n = 325), followed by moxifloxacin (13.5 %; n = 70), co-
amoxiclav (11.2 %; n = 58), cefuroxime (6.5 %; n = 34),
and clarithromycin (2.7 %; n = 14). Among the recorded
combination therapies in 47 patients, levofloxacin plus
cefuroxime was the most frequently used (34.0 %; n =
16) followed by levofloxacin plus co-amoxiclav (19.1 %;
n = 9).
The first follow-up visit was performed for the entire
study population (n = 684) and took place after a mean
of 9 days after hospital discharge. The second follow-up
consultation was performed for 27.3 % (n = 187 patients)
and took place after a mean of 11 days after first follow-up.
Data was collected either by telephone (63.6 %; n = 119,) or
during a hospital visit (36.4 %; n = 68).
During the two follow-up visits, participating physi-
cians considered that the treatment was successful in
almost all patients (>99.5 %) and adherence to CAP
therapy at home was reported by almost all patients
(>95.0 %) as well. However, radiographic assessment
was not performed in the majority of patients (>85 %),
so that this could not be used as a criterion for success.
Clinical CAP symptoms and signs were present in
25.4 % (n = 174) and in 2.0 % (n = 3) of the patients re-
spectively during the first and second follow-up visits.
Comparison of medical practices in the Gulf region with
CAP guidelines
The principal recommendations issued by the IDSA/
ATS guidelines are presented in Table 4, together with
the corresponding practice in Gulf countries as docu-
mented in the current study. The IDSA/ATS recom-
mends that for CAP cases, baseline history should
include considerations such as cough, fever, and previ-
ous hospitalisation for pneumonia, as well as additional
contributing risk factors. The study revealed that cough
(acute or changed character of chronic cough) was
found in 99 % of cases while pyrexia was observed in
98 % of CAP cases. During chest auscultation, positive
clinical findings (crepitations, late inspiratory crackles or
bronchial breathing) were documented in 80 % of study
participants.
As recommended by the IDSA/ATS guidelines, in
70 % (n = 483) of patients a chest radiograph was indica-
tive of new infiltrative changes. Moreover, to identify
high risk patients requiring hospitalisation, our study re-
ported that Gulf countries used the Fine criteria [13],
which is one of the instruments suggested in the IDSA/
ATS guidelines to identify patients with CAP who may
be candidates for outpatient treatment. In addition, the
most common CAP aetiological pathogens in the study
was S. pneumoniae, which is in line with the observa-
tions of the IDSA/ATS. However, the number of isolates
was limited (n = 78). Information about Gram’s staining
was not captured as recommended by the IDSA/ATS,
but data regarding the type of specimen used for isola-
tion of organism along with the type of test requested
were collected. Empirical antimicrobial therapy was initi-
ated immediately on the day of hospitalisation without
waiting for culture and sensitivity results, which is not
the recommended option. Moreover, it was reported that
in almost 95 % of subjects empirical antimicrobial ther-
apy was not changed after the isolation of organism. The
most frequent primary empiric therapy used was levo-
floxacin (fluoroquinolones), which is consistent with the
IDSA/ATS guidelines.
Discussion
This study was a multicentre, multinational, observa-
tional study which aimed to describe treatment practices
in CAP patients admitted to hospitals in five countries
in the Gulf region (United Arab Emirates, Kuwait,
Bahrain, Oman and Qatar) and to compare the findings
to the 2007 IDSA/ATS treatment guidelines. To our
knowledge, this is one of the first studies to assess treat-
ment standards, which has included a large sample of
patients to be conducted in the Gulf region.
Overall, our study shows that the management of
CAP in Gulf Arab countries participating in the study
is in line with the IDSA/ATS guidelines. For example,
Table 3 Frequency distribution and patterns of combination of
two antimicrobial agents in hospitalised CAP patients
(Total N = 139)
Levofloxacin Ceftriaxone Azithromycin Tazocin
Levofloxacin - - -
Ceftriaxone 31.7 % - -
Azithromycin 0.7 % 13.7 % -
Tazocin 9.4 % - 7.2 %
Co-amoxiclav 2.9 % - 8.6 % -
Clarithromycin 2.2 % 4.3 % - 0.7 %
Cefipime 3.6 % - - -
Amikacin 2.9 % - - -
Cefuroxime 2.9 % - -
Moxifloxacin - 2.2 % - 2.9 %
Ciprofloxacin - - 0.7 % -
Co-trimoxazole 0.7 % - - -
Gentamycin 0.7 % - - -
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information on cough and fever as one of the clinical
criteria for CAP was collected systematically and chest
radiography showed new infiltrative changes in the ma-
jority of patients (70.6 %).
However, for the rest of the population, a radiogram
was not performed or did not show new infiltrative
changes.
The type, route of administration and duration of anti-
microbial therapy was also generally consistent with the
IDSA/ATS guidelines for hospital ward treatment. Anti-
microbial therapy used in the Gulf region was in general
consistent with the recommendation of starting initial
therapy empirically with fluoroquinolones until labora-
tory results could be obtained to guide more specific
therapy. All patients received therapy initiated immedi-
ately on the day of hospitalisation, with fluoroquinolones
being the most widely used treatment. However, ten per-
cent of the study population received a combination of a
fluoroquinolone and a β-lactam during hospital admis-
sion, which is not the treatment recommended by the
IDSA/ATS expert panel for patients not admitted to an
ICU [2].
Table 4 The IDSA/ATS guidelines and corresponding practices in the Gulf region documented by the G-TinCAP study
IDSA/ATS steps guide [2] IDSA/ATS recommendations [2] Gulf practices according to G-TinCAP study
Make a correct
diagnostic of CAP
Consider cough, fever, and previous hospitalization
for pneumonia.
The study captured the information about cough and fever
as one of the clinical criteria for CAP.
Additional contributing risk factors for CAP include
viral infections, neutropenia, pulmonary edema,
altered consciousness, airway obstruction, and
congenital pulmonary abnormalities.
Accompanying diseases for vital organs and other
important information (eg malignancy, smoking and
immunocompetency) were included in the baseline medical
history.
Confirm the diagnosis Chest radiography should be carried out for all
suspected CAP patients to confirm the presence of
pneumonia.
Chest auscultation was performed to detect any positive clinical
findings (Crepitations, late inspiratory crackles or bronchial breathing).
70.6 % (n = 483) of the patient had new infiltrative changes
in the radiogram of the chest. For the rest of the population




Use IDSA/ATS algorithm to define which patients
would benefit from hospitalisation.
The Fine criteria [13], which use all the parameters included in
IDSA/ATS algorithm, were documented for all patients in this study.
Identify aetiologic agent
responsible for CAP
Streptococcus pneumoniae is the most common
etiologic agent for CAP.
Streptococcus pneumoniae alone was isolated in 46 % of cases
(n = 36 specimens). The combination of S. pneumoniae
and Klebsiella was isolated in 17 % of cases (n = 13 specimens).
Klebsiella alone and Mycoplasma alone were isolated
in 9 % (n = 7 specimens) and 8 % (n = 6 specimens) of cases
respectively. S. viridans, Moraxella cararrhalis and Legionella
were isolated in only 4 % of cases (n = 3 specimens).
Haemophilus influenzae and Chlamydia pneumoniae
are generally the third or fourth most common
organisms identified. Less common etiologic
agents include oral anaerobes, Staphylococcus
aureus, Legionella pneumophila and Moraxella
catarrhalis.
Establish the aetiology
and ensure that the
therapy is pathogen
directed
Use of sputum Gram’s stain and culture in all
patients, whenever possible.
Information about Gram’s staining was not captured, but data was
collected for the type of specimen used for isolation along with the
type of test requested. Sputum was the specimen most frequently
used.
Antimicrobial therapy Empiric antimicrobial therapy should be initiated
until laboratory results can be obtained to guide
more specific therapy.
In all participants, empirical antimicrobial therapy was initiated
immediately on the day of hospitalisation without waiting the
laboratory results (culture and sensitivity tests).
Either fluoroquinolones or macrolides plus
doxycycline are suggested for primary empiric
therapy.
Levofloxacin or moxifloxacin (fluoroquinolones) were the most
frequently used antimicrobial agents during hospital stay and after
hospital discharge.
Route of administration
for the antibiotic therapy
Switch to an appropriate oral antibiotic is
recommended as soon as the patient’s condition
is stable and he or she can tolerate oral therapy,
often within 72 h.
The mean duration of intravenous administration of CAP therapy was
around 81 h, though in 80 % of cases, switch to an oral antibiotic
occurred within 3 days (72 h).
Treatment duration As far as duration of treatment is concerned, the
treatment for S. pneumoniae should generally
continue for 7 to 14 days or until the patient is
afebrile for 72 h.
During hospitalisation, the mean duration of treatment with
antimicrobial agents was 3.5 days, ranging from 3 to 6 days.
Patients with atypical pathogens should be treated
for 10 to 21 days.
After hospital discharge, the mean duration of treatment with
antimicrobial agents was 7.4 days, ranging from 6 to 10 days.
Over 80 % of patients were prescribed a single antimicrobial agents
for their home antibiotic therapy after discharge from hospital.
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The pathogens responsible were not isolated and
characterised in the majority of patients and thus repre-
sent the major divergence between current practice in
the Gulf region and the IDSA/ATS guidelines. Charac-
terisation of CAP pathogens was only achieved in 12 %
of patients, principally by analysis of sputum samples.
In addition, information about use of Gram’s staining
method or any other methods used to identify pathogens,
was not collected in our study. The most frequently iden-
tified pathogen was Streptococcus pneumoniae, which is
consistent with findings from other countries, as noted in
the IDSA/ATS guidelines [2].
In 95 % of cases, the initial empiric therapy in our
study was not switched, suggesting that this empiric
therapy was effective. However, since the responsible
pathogen was not isolated in the majority of the patients,
it is not known whether the treatment was the most ap-
propriate in these patients. Once the patient was clinic-
ally stable, around 80 % of patients were switched to an
oral antibiotic within three days (72 h) as recommended
in the guidelines.
A further objective was to evaluate treatment outcome
at hospital discharge and up to approximately 3 weeks
after discharge. At hospital discharge, criteria for treat-
ment success were fulfilled by the majority of patients.
However, around one quarter of patients were dis-
charged before their leukocyte count had normalised. In
addition, it should be noted that at hospital discharge,
complete radiographic recovery was only detected in
around one-third of patients. Clinical signs related to
CAP were resolved in 97.9 % (n = 183) at the last follow-
up visit, performed around 3 weeks after discharge.
Our study identifies four areas in which current prac-
tice for management of CAP in the Gulf region falls
short of international guidelines and could be improved.
The first corresponds to isolation and characterisation
of the pathogenic agent, which needs to be performed
systematically. The lack of pathogen isolation in the ma-
jority of patients observed in the study may result in in-
appropriate antimicrobial therapy being prescribed and
thus expose patients to unnecessary risk.
The second relates to the failure to perform chest radi-
ography systematically at the post-discharge follow-up
visits, with around 90 % of patients not being assessed.
This may result in residual infection in the lungs being
missed and increase the risk of relapse if the physician
or patient decides to interrupt antimicrobial treatment.
Nonetheless, in everyday clinical practice in North
American and Europe, it is also common for follow-up
chest radiographs to be performed only if symptoms per-
sist or there is a clinical suspicion of infection [16].
The third relates to the fact that only one quarter of pa-
tients attended a second follow-up visit 3 weeks after dis-
charge. It would be important to encourage physicians to
collect information from their patients, either during a
formal hospital visit, and particularly if residual clinical or
radiological signs of infection were detected at the previ-
ous follow-up visit, or by telephone, 3 weeks after dis-
charge to ensure that the patient is effectively cured.
Finally, 10 % of the study population received a com-
bination of a fluoroquinolone and a β-lactam during
hospital admission, which is the treatment recom-
mended by the IDSA/ATS expert panel for patients dir-
ectly admitted to an ICU [2] and not for patients
included in our study (ie patients not directly admitted
to ICU). Consequently, in those patients the choice of
CAP antimicrobial therapy was not consistent with the
guidelines. Neverthless, at hospital admission, seven-
teen percent of patients (N = 117) were classified as
moderate to high risk for mortality according to the
Fine criteria [13] and consequently could be considered
by the physician to be eligible for an ICU regimen with-
out necessarily being directed to one. Because the over-
all efficacy of many classes of antimicrobial regimens is
considered to be good, over-treatment use is expected
to produce the same clinical outcome but with an in-
creased risk of antiobiotic resistance and side effects.
For this reason, the selection of antimicrobial regimens
for empirical therapy should be based on prediction of the
most likely pathogen and knowledge of local susceptibility
patterns with a preference given to the more potent drugs
because of their benefit in drecreasing the risk of selection
for antiobiotic resistance [2].
We compared treatment practices in CAP patients in
the Gulf region to the IDSA/ATS guidelines since they
are the most used guidelines worldwide, are well known
and used by doctors of the region and are one of the
recommended standard of care in the Gulf region.
The adherence to regional guidelines (ie GCC CAP
guidelines [12]) has already been evaluated in Oman
[11]. This analysis showed that there was very poor ad-
herence to the guidelines with respect to CAP severity
assessment and provision of preventive measures upon
hospital discharge and highlighted the necessity to im-
prove the implementation of such guidelines in the
region. Several studies have evaluated the level of ad-
herence to the IDSA/ATS guidelines. For instance, a re-
cent study from Italy performed in 191 patients with
CAP revealed that the adherence to antibiotic treat-
ment guidelines was poor, since only 47 % of patients
received an empirical antibiotic regimen that was ad-
herent to guidelines [17].
The enrolled patients were principally at low mortality
risk (82.9 %) according to the Pneumonia Severety Index
(PSI) developed by Fine [13], which assigns points based
on age, laboratory parameters, and the presence of dif-
ferent comorbidities. The PSI is one of the instruments
recommended by the IDSA/ATS panel in order to assess
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mortality risk and to identify patients with CAP who
may be candidates for outpatient treatment [2]. It has
been suggested that patients with risk class I and II
should be treated as outpatients, risk class III patients
should be treated in an observation unit or with a short
hospitalisation, and risk class IV and V patients should
be treated as inpatients [13]. In the present analysis, we
decided not to include patients with risk class I. We as-
sumed that those patients did not require a particular
hospital monitoring and are most often candidates for
outpatient treatment than that of other classes.
The proportion of patients considered at low mortality
risk (PSI II and III) was higher than that anticipated and
also higher than the rate reported in the literature. For
example, it has been reported that the rate of low-risk
patients hospitalised due to CAP in Israel, USA and
Western Europe was around 30 %[13, 14, 18, 19]. The
most likely explanation for this is that patients at high
risk, who in fact died during hospitalisation, are not cap-
tured in our study.
A principal limitation of our study is the lack of infor-
mation on methods used for pathogen identification and
the failure to characterise the pathogen in the majority
of patients, which compromises the quality of the data
collected. In particular, this may have led to less fre-
quent, but epidemiologically important, pathogens not
being detected.
A second major limitation relates to the mode of re-
cruitment of the patients, which precludes collecting in-
formation on in-hospital mortality. We were thus unable
to document mortality rates in our cohort, in particular
in patients with moderate to high risk mortality accord-
ing to the Fine criteria [13]. According to the literature,
the rate of mortality has been estimated to be low in the
Gulf region compared to other areas of the world. For
instance, the mortality rate among patients with pneu-
moniae has been estimated at 3.5 % (N = 6/172 patients)
in Oman [11] compared to 7.2 % (N = 147/ 2039 pa-
tients) in Europe [20].
A third limitation relates to the low mortality risk of
the majority of the patients enrolled. This may be a
consequence of exclusion of patients who required hos-
pitalisation in an ICU and failure to capture high risk
patients who died in hospital. In the sample size calcu-
lation, it was anticipated that 50 % of patients would be
at high risk, whereas in fact >80 % of patients were at
low risk. This enrichment in low-risk patients may have
led to an over-optimistic view of treatment outcome in
clinical practice, which may not apply to more severely-
ill patients. In addition, it is possible that standards of
care, in terms of adherence with IDSA/ATS guidelines,
may have been inferior in patients who died.
Finally, although we examined data from five Gulf
countries represented by 38 hospitals, the majority of
the study population (65 %; n = 444) came from the
United Arab Emirates, which may introduce some bias.
To a certain extent, the number of patients included re-
flects the demographic weight of each country, with
UAE having the highest population (8 million) in 2010,
followed by Kuwait and Oman (3 million each), Qatar
(1.8 million) and Bahrain (1.2 million) [21]. However,
the UAE is somewhat over-represented and Qatar and
Oman somewhat under-represented. In part this may be
explained by the number of hospitals available for re-
cruitment. The federal structure of the UAE has led to
the development of multiple autonomous health services
in each of the constituant emirates leading to a larger
number of hospitals per capita than in the other Gulf
countries. In contrast, in Oman and Qatar, the popula-
tion, and health care provision, is concentrated in the
capital city. The number of patients recruited in Oman
was particularly low (28). In comparison, a study per-
formed only in Oman [11] in a single centre and over a
similar study period to that of our study (2 years), in-
cluded a total of 170 patients. It is possible that there
was competition for patient recruitment between the
two studies. Moreover, all participating countries have
large populations of migrant workers whose socioeco-
nomic status differs from the local population. Socioeco-
nomic status may influence morbidity risk and
adherence with treatment following discharge and this
was not taken into account in our analysis. Finally, it
should be noted that our study did not include Saudi
Arabia, which is the largest country of the Gulf region.
Consequently, our results should not be generalised to
the entire Gulf region.
Conclusion
This study provides a valuable “snapshot“ of current
CAP treatment practices in the Gulf region and reveals
that the management of CAP in this region is generally
in line with current IDSA/ATS guidelines, although
rates of pathogen characterisation and post-discharge
follow-up need to be improved. This study highlights
the importance of improving the implementation of the
established guidelines in order to improve outcome of
patients with CAP in the Gulf region.
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